Appendix 4E and Preliminary Final Report
Filed with ASX · · 17 pages · English
Summary by 6ix AI
The report indicates a significant increase in total revenue from continuing operations, while the company experienced a substantial operating loss after tax. The loss for the year attributable to the owners of Anagenics Limited also saw a notable rise compared to the previous year, reflecting ongoing challenges in achieving profitability. The report highlights efforts to restructure the business and improve cash flows, although profitability remains a key focus moving forward.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Anagenics
- Company Update License Partnership Announcement
- Appendix 4C Cash Flow & Activities Report
- Midkine Antibody Licensing Deal
- Quarterly Activities/Appendix 4C Cash Flow Report
- Organisational Changes
Later from Anagenics
- FY24 4E Presentation
- Pause in Trading
- Suspension from Official Quotation
- Market Update
- 2024 Anagenics Annual Report
Follow Anagenics into a list and get an email when it puts out news.
Follow Anagenics